CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Novavax Earns $125 Million Milestone as Sanofi Starts Combination Vaccine Trial

By Public Technologies
  • Novavax earned a $125 million milestone on Oct. 29, 2026, as Sanofi began a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
  • The trial evaluates Nuvaxovid combined with Sanofi’s Efluelda/Fluzone High-Dose flu vaccine in adults aged 60 and older.
  • A further $75 million milestone is payable upon successful completion of manufacturing technology transfer, anticipated in mid-2027.
  • An additional $225 million milestone depends on a U.S. combination vaccine launch following successful completion of clinical and regulatory requirements.
  • The partnership also provides royalties on Sanofi’s Nuvaxovid sales, combination products using Nuvaxovid, and new vaccines using Matrix-M.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH84613) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk